Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemokines

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    92 result(s) found for: Chemokines. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2011-004910-41 Sponsor Protocol Number: WellmuneElderlyStudy1.1 Start Date*: 2011-12-30
    Sponsor Name:University of Southampton
    Full Title: A Randomised Controlled Trial to assess a food supplement (baker’s yeast extract) to support immune function and prevent cold and flu symptoms in a 50 to 70 year old population
    Medical condition: We aim to assess the number and severity of Upper Respiratory Tract Infection(URTI)Symptoms reported by participants over a 90 day period commencing in January 2012 in 100 healthy 50-70 year olds p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000077-39 Sponsor Protocol Number: RECOGITO_V1.0_2014 Start Date*: 2014-02-27
    Sponsor Name:Sapienza University of Rome
    Full Title: Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phospho...
    Medical condition: Diabetic Cardiomyopathy, Diabetes Mellitus Type 2, Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    16.1 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    16.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004799-50 Sponsor Protocol Number: PNEUMOREG Start Date*: 2015-02-13
    Sponsor Name:Federico Martinon Torres
    Full Title: Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control.
    Medical condition: Allergic asthma and type 1 diabetes mellitus in pediatric subjects.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005084-29 Sponsor Protocol Number: 1 Start Date*: 2006-03-23
    Sponsor Name:Chief Scientitst Office
    Full Title: The effect of intensive lipid lowering on markers of inflammation in patients with stable coronary artery disease.
    Medical condition: Patients with cardiovascular risk factors and stable coronary artery disease, with a fasting total cholesterol level ≥5 mmol/l.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-006644-19 Sponsor Protocol Number: CRISTAL Start Date*: 2009-01-29
    Sponsor Name:AZIENDA OSPEDALIERA SAN GERARDO DI MONZA
    Full Title: Evaluation of inflammatory immune parameters predicting cardiovascular risk in HIV-1-infected antiretroviral therapy naive patients treated with atazanavir/ritonavir versus lopinavir/ritonavir base...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002608-33 Sponsor Protocol Number: KI CLINTEC mikro 02 Start Date*: 2006-10-27
    Sponsor Name:Karolinska Institute, CLINTEC, div of orthopedics
    Full Title: En dubbelblind placebokontrollerad studie för utvärdering av postoperativa analgetikaeffekter via mikrodialys synovialt på patienter som genomgår artroskopi.
    Medical condition: Painfull knee condition of traumatic or other origin, where arthroscopic surgery is indicated, as judged by the surgeon.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002965-67 Sponsor Protocol Number: 57877.018.016 Start Date*: 2017-07-07
    Sponsor Name:AMC
    Full Title: An open, non-randomized, parallel-group pharmokinetic and -dynamic, investigator-initiated study on effects of obeticholic acid (OCA) in bile of patients with primary biliary cholangitis (PBC) and ...
    Medical condition: Primary biliairy cholangitis (PBC) Non-alcoholic steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003197-24 Sponsor Protocol Number: PL8177-106 Start Date*: 2020-03-16
    Sponsor Name:Palatin Technologies, Inc.
    Full Title: A Phase 2, Randomized, 3-Arm Parallel Group, Placebo and Active-Controlled Study of the Effect of PL8177 Administered via Subcutaneous Injection in Healthy Male Volunteers on Inflammatory Onset and...
    Medical condition: Inflammatory Onset and Resolution
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10053414 Application site blister LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000515-80 Sponsor Protocol Number: RIFA-AAH Start Date*: 2012-08-29
    Sponsor Name:Juan Córdoba
    Full Title: Effects of rifaximin administration in patients with severe acute alcoholic hepatitis. Comparative pilot study.
    Medical condition: Acute alcoholic hepatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10000649 Acute alcoholic hepatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-002060-34 Sponsor Protocol Number: V1.0 Start Date*: 2008-11-20
    Sponsor Name:Medizinische Universität Wien; Univ.Klin.f.Innere Med. III, Abt.f.Gastroenterologie u. Hepatologie
    Full Title: Impact of Inhibition of Thrombocyte Activation on the course of chronic Hepatitis C
    Medical condition: Chronic Hepatitis C
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-003897-30 Sponsor Protocol Number: AERD-COV19 Start Date*: 2022-05-30
    Sponsor Name:Jagiellonian University Medical College
    Full Title: Long-term aspirin therapy as a predictor of decreased susceptibility to SARS-CoV-2 infection in aspirin-exacerbated respiratory disease
    Medical condition: aspirin-exacerbated respiratory disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003534 Aspirin-sensitive asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10075084 Aspirin-exacerbated respiratory disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-005419-18 Sponsor Protocol Number: 01INMUNOGEST14 Start Date*: 2016-07-01
    Sponsor Name:silvia sanchez ramon
    Full Title: CLINICAL TRIAL, PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED WITH INTRAVENOUS IMMUNOGLOBULIN HUMAN FOR THE TREATMENT OF REPEAT ABORTION WITH IMMUNE ETIOLOGY
    Medical condition: recurrent aborption with inmunological etiology
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000883-27 Sponsor Protocol Number: Rif_CVID_260611 Start Date*: 2013-08-16
    Sponsor Name:Oslo University hospital
    Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
    Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023562-51 Sponsor Protocol Number: BT-CL-PGG-CRC1031 Start Date*: 2011-11-17
    Sponsor Name:Biothera
    Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-004497-15 Sponsor Protocol Number: ERGO Start Date*: 2016-12-12
    Sponsor Name:UMBERTO I - POLICLINICO DI ROMA
    Full Title: Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in C...
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005611-16 Sponsor Protocol Number: 52003 Start Date*: 2015-03-16
    Sponsor Name:Academic Medical Center, University of Amsterdam
    Full Title: Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients
    Medical condition: Mild asthmatics with house dust mite allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001396-33 Sponsor Protocol Number: EPA-COV-001 Start Date*: 2020-11-13
    Sponsor Name:SLA Pharma (UK) Ltd [...]
    1. SLA Pharma (UK) Ltd
    2. KD Swiss GmbH
    Full Title: A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001671-79 Sponsor Protocol Number: CAIN457ADE08 Start Date*: 2018-02-15
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, multicenter 28 week study to compare the efficacy and safety of combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) with a lifestyle intervention to Cosentyx therapy alone in adu...
    Medical condition: Moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002383-27 Sponsor Protocol Number: CHDR1806 Start Date*: 2019-08-01
    Sponsor Name:Centre for Human Drug Research
    Full Title: An exploratory, single-center, double-blinded, healthy volunteer controlled study to characterize psoriasis patients and explore novel biomarkers for the treatment response of psoriasis with a mult...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001717-20 Sponsor Protocol Number: COVIDIOL Start Date*: 2020-04-20
    Sponsor Name:Fundación para la Investigación Biomédica de Córdoba
    Full Title: Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)
    Medical condition: Severe Acute Respiratory Syndrome in subjects with COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061986 SARS LLT
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:16:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA